In a retrospective analysis conducted by the Mayo Clinic, involving 159 patients with MPO-ANCA AAV and renal complications from 1996 to 2015, the study assessed relapse rates, MPO-ANCA status, and the approaches to maintaining remission. The gene discussed is MPO; the disease is anti-neutrophil cytoplasmic antibody-associated vasculitis.